Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Eiger BioPharmaceuticals, Inc. [EIGR]
Reports for Purchase
Showing records 61 - 80 ( 112 total )
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lonafarnib Treatment Associated with Survival Benefit in Progeria
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sell-off on Ubenimex for PAH Overdone in Front of Multiple 2018 Data Releases
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ubenimex for Lymphedema: Phase 2 Enrollment Complete and Top-line Results in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Corporate Update and Outlook: Material Catalysts in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing shares of EIGR Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.